Literature DB >> 12411787

Detection of proton release from cultured human myotubes to identify malignant hyperthermia susceptibility.

Werner Klingler1, Christoph Baur, Michael Georgieff, Frank Lehmann-Horn, Werner Melzer.   

Abstract

BACKGROUND: Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle. During general anesthesia, a life-threatening hypermetabolic state may occur resulting from increased release of Ca2+ from the sarcoplasmic reticulum in skeletal muscle. Diagnosis of MH susceptibility requires surgical muscle biopsies to measure force in response to chemical stimulation (in vitro contracture test, IVCT). Here, the authors investigated an alternative way of discriminating MH-susceptible (MHS) from normal (MHN) subjects by using cultured human myotubes and measuring proton release as an indicator of cellular metabolism.
METHODS: Myotubes were stimulated with the Ca2+ release channel agonist 4-chloro-m-cresol (4-CmC), leading to metabolic activation and proton secretion. The rate of extracellular acidification was recorded with a silicon sensor chip.
RESULTS: A stepwise increase in 4-CmC concentration led to a phasic-tonic increase in the acidification rate. The response, measured at different concentrations of 4-CmC, was considerably larger in cultures from MHS compared with MHN subjects and correlated well with the force response in the IVCT.
CONCLUSIONS: The enhanced metabolism of cultured skeletal myotubes, likely originating from an increased myoplasmic Ca2+ concentration, can be monitored by studying the proton secretion rate. Because the method seems to be able to distinguish normal from pathologic phenotypes, it is a promising technique for possible future use in less invasive MH testing.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12411787     DOI: 10.1097/00000542-200211000-00006

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  3 in total

1.  Hypermetabolism in B-lymphocytes from malignant hyperthermia susceptible individuals.

Authors:  Kerstin Hoppe; Guido Hack; Frank Lehmann-Horn; Karin Jurkat-Rott; Scott Wearing; Alberto Zullo; Antonella Carsana; Werner Klingler
Journal:  Sci Rep       Date:  2016-09-20       Impact factor: 4.379

Review 2.  Malignant hyperthermia.

Authors:  Henry Rosenberg; Mark Davis; Danielle James; Neil Pollock; Kathryn Stowell
Journal:  Orphanet J Rare Dis       Date:  2007-04-24       Impact factor: 4.123

Review 3.  Malignant hyperthermia: a review.

Authors:  Henry Rosenberg; Neil Pollock; Anja Schiemann; Terasa Bulger; Kathryn Stowell
Journal:  Orphanet J Rare Dis       Date:  2015-08-04       Impact factor: 4.123

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.